[go: up one dir, main page]

AU2001294520A1 - Methods and compositions for increasing protein yield from a cell culture - Google Patents

Methods and compositions for increasing protein yield from a cell culture

Info

Publication number
AU2001294520A1
AU2001294520A1 AU2001294520A AU9452001A AU2001294520A1 AU 2001294520 A1 AU2001294520 A1 AU 2001294520A1 AU 2001294520 A AU2001294520 A AU 2001294520A AU 9452001 A AU9452001 A AU 9452001A AU 2001294520 A1 AU2001294520 A1 AU 2001294520A1
Authority
AU
Australia
Prior art keywords
compositions
methods
cell culture
protein yield
increasing protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294520A
Inventor
Todd Bucciarelli
Victor Levenson
Thomas Primiano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clonex Development Inc
Original Assignee
Clonex Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clonex Development Inc filed Critical Clonex Development Inc
Publication of AU2001294520A1 publication Critical patent/AU2001294520A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2001294520A 2000-08-21 2001-08-21 Methods and compositions for increasing protein yield from a cell culture Abandoned AU2001294520A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22629000P 2000-08-21 2000-08-21
US60/226,290 2000-08-21
PCT/US2001/026157 WO2002016590A2 (en) 2000-08-21 2001-08-21 Methods and compositions for increasing protein yield from a cell culture

Publications (1)

Publication Number Publication Date
AU2001294520A1 true AU2001294520A1 (en) 2002-03-04

Family

ID=22848318

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294520A Abandoned AU2001294520A1 (en) 2000-08-21 2001-08-21 Methods and compositions for increasing protein yield from a cell culture

Country Status (3)

Country Link
US (3) US6635448B2 (en)
AU (1) AU2001294520A1 (en)
WO (1) WO2002016590A2 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL136232A0 (en) * 2000-05-18 2001-05-20 Bar Ilan University Res Author Measurements of enzymatic activity in a single, individual cell in population
AU2001294520A1 (en) * 2000-08-21 2002-03-04 Clonex Development, Inc. Methods and compositions for increasing protein yield from a cell culture
IL154677A0 (en) * 2003-02-27 2003-09-17 Univ Bar Ilan A method and apparatus for manipulating an individual cell
US7611885B2 (en) * 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
US9200245B2 (en) 2003-06-26 2015-12-01 Seng Enterprises Ltd. Multiwell plate
US7888110B2 (en) 2003-06-26 2011-02-15 Seng Enterprises Ltd. Pico liter well holding device and method of making the same
US8597597B2 (en) 2003-06-26 2013-12-03 Seng Enterprises Ltd. Picoliter well holding device and method of making the same
WO2005008626A1 (en) * 2003-07-11 2005-01-27 University Of North Carolina At Chapel Hill Methods and systems for controlling a computer using a video image and for combining the video image with a computer desktop
US20050064524A1 (en) * 2003-08-11 2005-03-24 Mordechai Deutsch Population of cells utilizable for substance detection and methods and devices using same
DK1694361T3 (en) 2003-12-09 2011-06-06 Engeneic Molecular Delivery Pty Ltd Targeted delivery to non-phagocytic mammalian cells via bacterially derived intact minicells
PT1718338E (en) 2004-02-02 2015-09-21 Engeneic Molecular Delivery Pty Ltd Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
US8772013B2 (en) * 2004-02-02 2014-07-08 Engeneic Molecular Delivery Pty Ltd Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
AU2005210236B2 (en) * 2004-02-03 2010-09-09 Chemagis Ltd. Stable amorphous forms of montelukast sodium
EP1763665A1 (en) * 2004-07-07 2007-03-21 Seng Enterprises Limited Method and device for identifying an image of a well in an image of a well-bearing component
US7403647B2 (en) * 2004-09-13 2008-07-22 Seng Enterprises Ltd. Method for identifying an image of a well in an image of a well-bearing component
US7531327B2 (en) 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US7537930B2 (en) * 2004-07-23 2009-05-26 Immunomedics, Inc. Mammalian cell lines for increasing longevity and protein yield from a cell culture
US7608425B2 (en) * 2004-07-23 2009-10-27 Immunomedics, Inc. Methods for protein expression in mammalian cells in serum-free medium
HUE024999T2 (en) 2004-08-26 2016-02-29 Engeneic Molecular Delivery Pty Ltd Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
EP1786911A1 (en) * 2004-09-07 2007-05-23 Clonex Development, Inc. Cell lines for use in increasing protein yield from a cell culture
EP1866075B1 (en) 2005-01-25 2010-09-08 Seng Enterprises Limited Microfluidic device for studying cells
US20070092947A1 (en) * 2005-10-20 2007-04-26 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
WO2007052245A1 (en) 2005-11-03 2007-05-10 Seng Enterprises Ltd. Method and device for studying floating, living cells
EP1994155B2 (en) 2006-02-13 2022-05-04 Daiichi Sankyo Company, Limited Polynucleotide and polypeptide sequences involved in the process of bone remodeling
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US20060223999A1 (en) * 2006-05-10 2006-10-05 Chemagis Ltd. Process for preparing montelukast and precursors thereof
CA2658058C (en) * 2006-06-23 2016-08-23 Engeneic Molecular Delivery Pty Ltd. Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TWI548747B (en) 2006-09-13 2016-09-11 艾伯維有限公司 Cell culture improvement
US20090142839A1 (en) * 2007-05-04 2009-06-04 Shiloh Laboratories, Inc. Inducing Premature Senescence to Stabilize Stem Cell Feeder Layer Cells
US9975118B2 (en) 2007-11-15 2018-05-22 Seng Enterprises Ltd. Device for the study of living cells
US9145540B1 (en) 2007-11-15 2015-09-29 Seng Enterprises Ltd. Device for the study of living cells
RU2551237C2 (en) 2008-10-20 2015-05-20 Эббви Инк Virus inactivation in antibody purification
RU2520838C2 (en) 2008-10-20 2014-06-27 Эббви Инк Separation and purification of antibodies with application of protein a-based affinity chromatography
BR112013000219B1 (en) 2010-07-05 2021-06-01 Lonza Ltd METHOD FOR THE PRODUCTION OF A RECOMBINANT POI, A HIGH-PRODUCING CELL LINE AND A HIGH-PRODUCING CELL CULTURE, METHODS FOR INCREASE YIELD AND PROLONGING THE PRODUCTION PHASE OF A POL
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
EP2875051B1 (en) 2012-07-19 2019-02-20 Daiichi Sankyo Company, Limited Anti-siglec-15 antibodies
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2890782A1 (en) 2012-09-02 2015-07-08 AbbVie Inc. Methods to control protein heterogeneity
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US588981A (en) * 1897-08-31 Lace-fastener
WO1994004672A1 (en) * 1992-08-26 1994-03-03 Dnx Corp. Tetracycline repressor-mediated binary regulation system for control of gene expression in transgenic animals
US5888981A (en) * 1993-06-14 1999-03-30 Basf Aktiengesellschaft Methods for regulating gene expression
US5891718A (en) * 1996-03-27 1999-04-06 Vical Incorporated Tetracycline inducible/repressible systems
US6274341B1 (en) 1997-10-09 2001-08-14 James E. Bailey Cytostatic process increases the productivity of cultured cells
AU2001294520A1 (en) * 2000-08-21 2002-03-04 Clonex Development, Inc. Methods and compositions for increasing protein yield from a cell culture

Also Published As

Publication number Publication date
US7384776B2 (en) 2008-06-10
US7851219B2 (en) 2010-12-14
US20090142828A1 (en) 2009-06-04
WO2002016590A3 (en) 2002-08-15
US20050074856A1 (en) 2005-04-07
US20020160450A1 (en) 2002-10-31
US6635448B2 (en) 2003-10-21
WO2002016590A2 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
AU2001294520A1 (en) Methods and compositions for increasing protein yield from a cell culture
AU2002230527A1 (en) Mailer for cell culture apparatus
AU2001234608A1 (en) Methods for analysis of gene expression
AU2002319780A1 (en) Alternative compositions and methods for the culture of stem cells
AU6860301A (en) Methods and compositions for simultaneous saccharification and fermentation
AU2001250036A1 (en) Microdroplet cell culture technique
AU2002303343A1 (en) Methods and reagents for cell transplantation
AU2003260351A1 (en) Cell culture insert
AU2002325758A1 (en) Cultured stromal cells and uses thereof
AU2003216822A1 (en) Stem cell culture
AU2001235452A1 (en) Cell culture media
AU2002214126A1 (en) Genetic analysis of microorganisms
AU2002220553A1 (en) Bioreactor
AU3178200A (en) Genetic analysis
AU1571801A (en) Improved fermentation process
AU2001275897A1 (en) Improvement of cell culture performance
AU5061300A (en) Microchamber for embryo cell culture
AU3961600A (en) Method for increasing the yield of grain biomass per area
AU2002257064A1 (en) Methods for isolating proteins expressed by dendritic cells
AU2370901A (en) Methods for collecting genetic material
AU5622201A (en) Method for isolating in vitro differentiated somatic cells
AU2002211537A1 (en) Culture of goblet cells
AU2003264279A1 (en) Growth factor for cell culture
AU2001257343A1 (en) Holder for cell culture devices
AU4203400A (en) Plant viral movement protein genes